AIV001
Phase 1Small molecule
AIV001 is one of 118 small molecule programs targeting Wound Healing. It is currently in Phase 1.
4
Indications
4
Total Trials
0
Active Trials
117
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
133 competitors in Wound Healing
#DrugCompanyPhaseTrials
1Avastin
BBio-Thera Solutions
Phase 3
Januvia
ZZydus Therapeutics Inc.
Phase 3
Glucophage
EMD SeronoPhase 3
Growth Hormone
PfizerPhase 3
Vaseline
MMassachusetts General Hospital
Phase 3
Insulin Regular
TThe University of Texas Medical Branch, Galveston
Phase 3
Becaplermin
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Zofran
NovartisPreclinical
Nicorette
PfizerPreclinical
Restasis
TTaiwan Bio Therapeutics Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Wound Healing1 trial
Keloid1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AIV001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAiViva BioPharma, Inc.